Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win - BioSpace
Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win BioSpace
Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win BioSpace
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.